Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor-positive advanced breast cancer

Share :
Published: 28 Jan 2010
Views: 9077
Rating:
Save
Dr Angelo Di Leo - Hospital of Prato, Italy
A higher dose of fulvestrant is well tolerated and more active than the standard, lower dose in postmenopausal patients with advanced breast cancer. "We believe that, based on the results of this study, treatment and practice should change; patients should receive the 500 mg dose," said Angelo Di Leo, M.D., Ph.D., director of the Department of Oncology at the Hospital of Prato, Italy. Official San Antonio Breast Cancer Symposium press conference.

Watch Dr Di Leo speaking to ecancertv about the research he is presenting at SABCS 2009.
Watch Dr Di Leo speaking about fulvestrant dose at the SABCS 2008 official press conference.